93
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

, , &
Pages 349-359 | Published online: 22 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ying Zheng, Ting Yu, Rachel H Mackey, Julie A Gayle, Christina L Wassel, Hemant Phatak & Ruth Kim. (2021) Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. ClinicoEconomics and Outcomes Research 13, pages 213-226.
Read now

Articles from other publishers (3)

Ivo AbrahamAmit GoyalBaris DenizDonald MoranMarc ChiodaKaren M MacDonaldHuan Huang. (2022) Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States. Journal of Managed Care & Specialty Pharmacy 28:4, pages 435-448.
Crossref
Khadidja Abdallah, Isabelle Huys, Kathleen Claes & Steven Simoens. (2021) Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review. Frontiers in Pharmacology 12.
Crossref
. (2019) Assessing budget impact of avelumab in Merkel cell carcinoma. PharmacoEconomics & Outcomes News 829:1, pages 4-4.
Crossref